# Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

> **NCT01858181** · PHASE1 · UNKNOWN · sponsor: **Mentrik Biotech, LLC** · enrollment: 9 (estimated)

## Conditions studied

- Previously Treated CD20+ B-cell Malignancies

## Interventions

- **BIOLOGICAL:** ocaratuzumab

## Key facts

- **NCT ID:** NCT01858181
- **Lead sponsor:** Mentrik Biotech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2015-12
- **Final completion:** —
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2014-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858181, "Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01858181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*